Clinical

Obesity is a serious and costly disease that is growing in epidemic proportions. Obesity-related hospitalizations have nearly tripled from 1996 to 2009. If the current trend in the growth of obesity continues, the total healthcare costs attributable to obesity could reach $861 billion to $957 billion by 2030. The American Medical Association has officially recognized obesity as a disease. Obesity is a public health crisis affecting approximately more than 33% of Americans and costing the healthcare system more than $190 billion annually.
The Modern Epidemic of Obesity

According to the American Cancer Society, more than 1.6 million people will receive a new diagnosis of cancer in 2013.1 It is also estimated that there were almost 14 million cancer survivors (ie, any living person who has ever received a diagnosis of cancer) in the United States in 2012.2 Although many aggressive forms of cancer still exist, individuals who receive a diagnosis of cancer today are less likely to die from their disease than in the past; the death rate from cancer has decreased by 20% since 1991.1 However, the number of cancer diagnoses is inc

Quality of Cancer Care: Emerging Definition and Measurements, but Reimbursement Lagging

Rosacea is a common and chronic skin disorder with characteristic signs and symptoms, including flushing, facial erythema, inflammatory papules and pustules, telangiectasia, edema, and watery or irritated eyes.1 Four clinical subtypes of rosacea have been characterized, including erythematotelangiectatic, papulopustular, phymatous, and ocular.2 It is common for patients to present with more than 1 subtype.

The Psychosocial Impact of Skin Disorders: Time for a Closer Look?

Rosacea is a common and chronic skin disorder with characteristic signs and symptoms, including flushing, facial erythema, inflammatory papules and pustules, telangiectasia, edema, and watery or irritated eyes.1 Four clinical subtypes of rosacea have been characterized, including erythematotelangiectatic, papulopustular, phymatous, and ocular.2 It is common for patients to present with more than 1 subtype.

The Psychosocial Impact of Skin Disorders: Time for a Closer Look?

A patient-reported outcome (PRO) is a subjective report that comes directly from a patient in regard to his or her health condition or treatment without interpretation by a clinician or anyone else.1 PROs have long provided a unique insight into the effectiveness of novel medical treatments.2 Indeed, PRO questionnaires have been developed to quantify a patient’s self-reported health status in a variety of areas, including symptoms, functioning, quality of life (QOL), and health-related QOL.

Assessing the Value of Patient-Reported Outcomes

Diabetic peripheral neuropathy (DPN) is one of the most common complications associated with diabetes, occurring in 30% to 50% of patients with type 2 diabetes and affecting approximately 1 million Americans annually.1,2 DPN manifests as spontaneous painful, burning, electric, or shooting sensations in the extremities, with 10% to 20% of patients with DPN experiencing moderate-to-severe pain.3-6 Of these patients, 11% to 26% develop chronic pain, which is defined as pain that continues for an extended period of time that may be associated with a recognizable disease process.

Monitoring for Aberrant Opioid Utilization Patterns a Growing Need in Managed Care

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes pain, stiffness, swelling, and loss of function in the joints; it occurs when the patient’s immune system attacks healthy tissue. RA is ranked among the highest of all chronic diseases for its adverse impact on health-related quality of life (QOL), limitations in physical function, increased pain and fatigue, and diminished work performance and attendance.1

Assessing the Value of TNF-Alpha Blockers for Patients with Rheumatoid Arthritis

Preventable medication errors have emerged as a prominent cost and quality issue in the United States, and are estimated to impact more than 7 million patients, contribute to 7000 deaths, and cost almost $21 billion in direct medical costs across all care settings annually.1,2 Adverse drug events (ADEs) are harms that result from medication use; when these harms result from a medication error, they are known as “preventable ADEs.”3 The inpatient hospital setting is particularly resource-intensive in terms of care delivered and exposure to potential harms a

Parkinson’s disease is a degenerative disorder that is characterized by muscle rigidity, tremors, and motor impairment that often results in progressive disability and severe complications that seriously affect a patient’s health-related quality of life (QOL) and physical functioning.

Parkinson’s Disease: A Complicated but Underappreciated and Undertreated Condition

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, diagnosed in approximately 1% of the general population.1 It is estimated that AF currently affects more than 2 million people in the United States and more than 4 million across the European Union, with the number of US patients with AF estimated to increase 2.5-fold by the year 2050.1,2

The Enormous Impact of Atrial Fibrillation and Stroke on Patients, Payers, and Society
Page 7 of 12
Results 61 - 70 of 114
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME